Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nivolumab + endocrine therapy + radiation therapy
- Development stage
- Unknown
- Lead developer
- Kyoto Breast Cancer Research Network
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This combination therapy consists of the immune checkpoint inhibitor nivolumab, endocrine (hormone) therapy, and palliative radiation therapy. It was specifically evaluated in Cohort A of a Phase Ib/II clinical trial (KBCRN-B13) conducted by the Kyoto Breast Cancer Research Network for the treatment of hormone receptor-positive (luminal-like), HER2-negative metastatic breast cancer with bone metastases. Nivolumab is a monoclonal antibody that targets the PD-1 receptor to restore T-cell anti-tumor activity. The regimen combines this immunotherapy with standard endocrine therapy and a single 8 Gy fraction of radiation to bone metastases, aiming to trigger an abscopal effect and improve systemic disease control. Results from Cohort A demonstrated that the combination is safe with modest clinical activity, showing an objective response rate of 11% and a disease control rate of 39%.
- Brand names
- Opdivo
- Other names
- Nivolumab plus radiation and hormone therapyNivolumab + endocrine therapy + RTCohort A-Kyoto Breast Cancer Research Network-breast cancer
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)ESR1 (ERα)
Beyond the preview
Go deeper on nivolumab + endocrine therapy + radiation therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nivolumab + endocrine therapy + radiation therapy.